3 Undervalued Biotechnology & Medical Research Stocks for Monday, February 26
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Monday, February 26 based on AAII’s Stock Grades.Grace Malone
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Grace Malone
Jack Gilleland
Jenna Brashear
Cynthia McLaughlin
Jack Gilleland
| Share Statistics | SNES | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.9 | $421.0 | 4% |
|
| Shares Out (Mil) | 5.3 | 46.5 | 15% |
|
| Institutional Ownership | 40.6% | 82.0% | 16% |
|
| Float (Mil) | 2.1 | 48.3 | 6% |
|
| Beta | 0.11 | 0.68 | 8% |
|
| Avg Daily Volume (000s) | 72 | 348 | 32% |
|
| Price Change (52-week) |
(74.0%) | 52.0% | 11% |
|
| Growth | SNES | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.0% | 6.6% | 96% |
|
| Net Income (5yr) | 4.1% | (1.6%) | 46% |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SNES | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $289 | 3% |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 31% |
|
| EPS (TTM) | ($1.364) | ($0.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($7) | 23% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $1 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $5 | $331 | 7% |
|
| Valuation | SNES | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.63 | 2.27 | 15% |
|
| P/E | na | 24.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SNES | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.5% | 69.4% | 81% |
|
| Net Margin | (275.3%) | 3.9% | 4% |
|
| ROA | (70.7%) | (23.8%) | 8% |
|
| ROE | (107.4%) | (24.7%) | 8% |
|
| Liabilities to Assets | 35.8% | 32.0% | 27% |
|
| F-Score | 4 | 3 | 33% |
|
SenesTech, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors